S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY

Abstract

Introduction.- Cognitive impairment significantly contributes to the functional impairment associated with schizophrenia. Objective.-To evaluate the longer-term effects of lurasidone on cognition in children and adolescents with schizophrenia. Methods.- Patients aged 13-17 years with schizophrenia who completed 6weeks of double-blind (DB), placebo-controlled treatment with lurasidone were enrolled in a 2-year, open-label study in which patients were continued on lurasidone or switched from placebo to lurasidone. Cognitive function was assessed with the Brief CogState battery, which evaluates four cognitive domains: processing speed (detection task), attention/vigilance (identification task), visual learning (one card learning task), workingmemory (one back task, speed & accuracy). Based on normative data, an overall cognitive composite Z-score was calculated as the average of the standardized Z-scores for each of the four cognitive domains. These results are from a 52-week interim data analysis. Results.- A total of 271 patients who completed the 6-week DB study entered the open-label extension study, and 75.6% completed 52 weeks of treatment (mean daily dose, 52.6 mg). The cognitive composite Z-score showed impairment at DB baseline (-1.09). At week 28, overall improvement was observed in the cognitive composite Z-score (mean change, +0.16). For CogState domains, mean change at week 52 in Z-scores was -0.02 for processing speed, 0.00 for attention/vigilance, +0.45 for visual learning, +0.24 for working memory accuracy, and +0.23 for working memory speed. Conclusions.- In this study of adolescents with schizophrenia, lurasidone was not associated with cognitive impairment after 52 weeks of treatment; improvement was noted in selected cognitive domains. Sponsored by Sunovion Pharmaceuticals Inc.